Can Oncotype Predict Recurrence Risk in Older BC Patients?

Published Date: 22 Apr 2026

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Read Full News

Latest News

Breast Cancer Incidence Rises in Asian American Women

A cross-sectional population-based study examines trends in invasive breast cancer incidence rates in Asian American, Native Hawaiian, and Pacific Islander ethnic groups.

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Induction Immunotherapy Has Durable Survival Benefit in LACC

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Todays Updates

A Sinister Etiology for Shoulder Pain

Patient presented with what was assumed to be rotator cuff injury

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Consistently low PSA levels failed to signal metastasis

Study Hints at Survival Benefit With Transplant for Metastatic Lung Cancer

— Substantially longer 1-year survival observed in rare subset of patients with lung-only disease

Todays Updates

A Sinister Etiology for Shoulder Pain

Patient presented with what was assumed to be rotator cuff injury

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Consistently low PSA levels failed to signal metastasis

Study Hints at Survival Benefit With Transplant for Metastatic Lung Cancer

— Substantially longer 1-year survival observed in rare subset of patients with lung-only disease

Latest News

A cross-sectional population-based study examines trends in invasive breast cancer incidence rates in Asian American, Native Hawaiian, and Pacific Islander ethnic groups.

Researchers seek to understand why Asian women fare better with the disease.

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

News All Time

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

The Growing Role of AI in Cancer Treatment

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Pain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Recommended News For You

Do I qualify for a cancer clinical trial?

Can Oncotype Predict Recurrence Risk in Older BC Patients?

For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC

Recommended Articles For You

Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment 

Emerging Frameworks in Oncology in Clinical Decision-Making 

The Millionaire's Battle: Does Mark Cuban Have Cancer? 

Introduction to Immune Thrombocytopenic Purpura 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.

2.

Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients

3.

PSA Screening May Modestly Curb Prostate Cancer Deaths

4.

Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.

5.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

1.

Exploring New Treatment Options for Hemophilia: A Journey into the Unknown

2.

Understanding Mean Corpuscular Volume: A Comprehensive Guide 

3.

Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy

4.

Subarachnoid Hemorrhage: Emerging Insights into Pathophysiology and Future Management

5.

Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI

2.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

3.

Navigating the Complexities of Ph Negative ALL - Part XV

4.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

5.

Efficient Management of First line ALK-rearranged NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot